Abstract

Two years ago we discussed the value of various measures, including low-dose subcutaneous heparin, in the prevention of deep-vein thrombosis.¹ We concluded that heparin used in this way lowers the incidence of deep-vein thrombosis after most major operations and that it is safe, cheap and simple to administer. Subsequent experience summarised in this issue has confirmed these conclusions. How widely is this treatment now used?